Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Twinlab

This article was originally published in The Tan Sheet

Executive Summary

Firm's common stock will be transferred to NASDAQ SmallCap Market effective Sept. 30, Hauppauge, N.Y.-based company announces Sept. 18. NASDAQ approved firm's application to move stock from National Market after setting Sept. 16 deadline for Twinlab to reply regarding its failure to meet market's $1 minimum listing price (1"The Tan Sheet" Aug. 5, 2002, p. 11)...

You may also be interested in...



Business & Financial News In Brief

Weider Nutrition brand divestiture: Optimum Nutrition subsidiary American Body Building picks up Weider's Science Foods, American Body Building brands in transaction that closed July 26. Deal affects 75-100 SKUs - primarily drinks and some bars - with total annual sales of slightly more than $20 mil. Transaction's total cost was not released, but final price includes roughly $5.7 mil. cash, assumption of approximately $250,000 mortgage on Walterborough, S.C. beverage manufacturing facility that was part of the deal. Acquisition gives Optimum Nutrition expanded line of beverages to complement current offerings of powders, capsules, bars. Weider says it will use net proceeds to reduce long-term debt, and transaction will negatively impact FY 2002 pre-tax financials by $8.7 mil.-$9.5 mil. Sale is part of Weider's effort to focus resources on Schiff Specialty Nutrition, Active Nutrition and Haleko business units...

Yes For Shionogi But No For Lilly In Latest EMA Recommendations

The European Medicines Agency says that Shionogi’s novel antibiotic, Fetcroja, should be approved for use across Europe but that Lilly's migraine drug, Emgality, should not be authorized for the extended indication of episodic cluster headache.

UK To Seek Only Limited Regulatory Alignment With EU

Despite the life sciences industry’s call for continued alignment of medicines regulation with the EU from next year and for some sort of co-operation with the European Medicines Agency, it seems the UK government is prepared to make only small concessions.

Topics

UsernamePublicRestriction

Register

PS094570

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel